Wells Fargo’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56,429
| Closed | -$1.21M | – | 7366 |
|
|
2026
Q1 | $1.21M | Sell |
56,429
-58,287
| -51% | -$821K | ﹤0.01% | 3625 |
|
|
2025
Q4 | $1.07M | Buy |
114,716
+33,248
| +41% | +$278K | ﹤0.01% | 3919 |
|
|
2025
Q3 | $574K | Buy |
81,468
+8,901
| +12% | +$61.2K | ﹤0.01% | 4208 |
|
|
2025
Q2 | $472K | Buy |
72,567
+18,871
| +35% | +$130K | ﹤0.01% | 4191 |
|
|
2025
Q1 | $426K | Buy |
53,696
+1,961
| +4% | +$21.1K | ﹤0.01% | 4212 |
|
|
2024
Q4 | $655K | Sell |
51,735
-4,744
| -8% | -$66K | ﹤0.01% | 3999 |
|
|
2024
Q3 | $787K | Sell |
56,479
-457
| -0.8% | -$6.52K | ﹤0.01% | 3694 |
|
|
2024
Q2 | $785K | Buy |
56,936
+11,175
| +24% | +$164K | ﹤0.01% | 3650 |
|
|
2024
Q1 | $756K | Buy |
45,761
+7,536
| +20% | +$113K | ﹤0.01% | 3621 |
|
|
2023
Q4 | $558K | Sell |
38,225
-39,386
| -51% | -$477K | ﹤0.01% | 3787 |
|
|
2023
Q3 | $952K | Sell |
77,611
-13,350
| -15% | -$174K | ﹤0.01% | 3367 |
|
|
2023
Q2 | $1.09M | Buy |
90,961
+33,403
| +58% | +$436K | ﹤0.01% | 3415 |
|
|
2023
Q1 | $770K | Buy |
57,558
+36,837
| +178% | +$720K | ﹤0.01% | 3563 |
|
|
2022
Q4 | $446K | Sell |
20,721
-258
| -1% | -$5.29K | ﹤0.01% | 3712 |
|
|
2022
Q3 | $420K | Buy |
20,979
+767
| +4% | +$16.3K | ﹤0.01% | 3803 |
|
|
2022
Q2 | $362K | Buy |
20,212
+10,212
| +102% | +$105K | ﹤0.01% | 3939 |
|
|
2022
Q1 | $99K | Sell |
10,000
-652
| -6% | -$8.61K | ﹤0.01% | 5337 |
|
|
2021
Q4 | $180K | Buy |
10,652
+599
| +6% | +$12.3K | ﹤0.01% | 5322 |
|
|
2021
Q3 | $238K | Buy |
+10,053
| New | +$241K | ﹤0.01% | 5024 |
|
Other funds holding DAWN
Wells Fargo's DAWN Position: Q2 2026 in Review
Wells Fargo sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 56,429 shares — an estimated $1.21M sold.
Wells Fargo first reported a position in DAWN in Q3 2021 and held it in 19 quarters. The position peaked at $1.21M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Wells Fargo reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Wells Fargo sold 56,429 Day One Biopharmaceuticals shares in Q2 2026, an estimated $1.21M.
- Wells Fargo first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 19 quarters.
- Wells Fargo's Day One Biopharmaceuticals position peaked at $1.21M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.